Drug Trial Radar · NCT04986423
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 8, 2021
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Zenith EpigeneticsIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.
- First posted
- Aug 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone Cohort B: Patients with response to prior abiraterone, defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694Drug
72 mg PO QD
EnzalutamideDrug
160 mg PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Radiographic progression-free survival (rPFS) by BICRTime frame: Randomization up to 30 months
Locations
31 sites in 2 countries. Site status is shown where the registry gives one.
California Research Institute
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Innovative Clinical Research Institute
Whittier, California · Recruiting
Colorado Urology
Lakewood, Colorado · Recruiting
D&H Cancer Research Center, LLC
Margate, Florida · Recruiting
BRCR Global
Plantation, Florida · Recruiting
Hematology Oncology Clinic
Baton Rouge, Louisiana · Withdrawn
Maryland Oncology Hematology, P.A.
Columbia, Maryland · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York · Completed
Messino Cancer Center
Asheville, North Carolina · Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon · Recruiting
Urology Associates, P.C.
Nashville, Tennessee · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Seattle Cancer Care Alliance
Seattle, Washington · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Withdrawn
The First Affiliated Hospital of Xi'an Jiaotang University
Xi'an, Shaanxi, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.